MGTX:NASDAQ, MeiraGTx Holdings plc

MGTX stock overview

MeiraGTx Holdings plc (MGTX:NASDAQ) closed at $9.21 on October 23, 2026, down 5.73% on the day. The stock trades 40.0% below its 52-week high of $15.35 and 39.1% above its 52-week low of $6.62. Over the past year, it gained 5.6%. MeiraGTx Holdings plc is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price

$9.21

Day change

-5.73%

Volume

595,502

Average volume

797,496

Market cap

884M+

52-week range

$6.62 – $15.35

50-day average

$12.25

200-day average

$10.25

Price action over the past year

In 252 trading sessions since October 23, 2025, MGTX closed higher on 119 days (47%). Its best day was April 14, 2026 (+17.24%) and its worst was April 16, 2026 (-15.73%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

• Oct 23, 2026: Down 25.1% over 90 days, from $12.30 (Dips & Crashes scanner)
• Oct 23, 2026: Trading sideways between $9.21 and $10.38 over 14 days (Sideways scanner)
• Oct 23, 2026: Hit a new 3-Month Low of $9.21 (New Highs/Lows scanner)

MGTX news

• Sep 23, 2026: MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
• Aug 26, 2026: Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
• Aug 14, 2026: What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?
• Aug 14, 2026: MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says
• Aug 13, 2026: MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
• Aug 13, 2026: MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
• Aug 12, 2026: TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
• Aug 11, 2026: Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

About MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.

Similar stocks

• REPL:NASDAQ
• SLDB:NASDAQ
• DBVT:NASDAQ
• ENTX:NASDAQ
• MESO:NASDAQ
• NVAX:NASDAQ
• RGNX:NASDAQ
• ALLO:NASDAQ

Find more stocks like MGTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.